Alkermes (NASDAQ: ALKS) Stock: Insider Sales, Institutional Moves, and Financial Outlook

• An Alkermes officer recently sold a significant number of shares, while institutional investors showed mixed activity in the pharmaceutical stock.
• Alkermes reported break-even earnings for Q2 2026 but exceeded revenue expectations with strong growth.
• The company reaffirmed its 2026 revenue guidance and is progressing with its late-stage drug candidate, alixorexton, in its drug development pipeline.

Alkermes (NASDAQ: ALKS) is a pharmaceutical company focused on developing treatments for central nervous system diseases. Amid recent company developments, an officer, Gaffin David Joseph, sold 2,034 Ordinary Shares at $48.58 each. This transaction leaves the executive with an ownership of 225,456 shares in Alkermes.

This insider sale coincides with notable trading from large institutional investors. Glenmede Trust Co. NA decreased its investment in Alkermes by 8.4%, selling 34,830 shares. The firm now holds 378,090 shares, a position valued at approximately $13.40 million at the end of the first quarter.

However, not all institutions are reducing their positions. Cullen Frost Bankers Inc. and Johnson Financial Group Inc. both established new stakes in Alkermes, worth around $28,000 and $31,000, respectively. Additionally, UMB Bank n.a. increased its holdings by 57.6% to a total of 1,220 shares, reflecting varied investor sentiment.

These transactions follow the company's recent financial report. As highlighted by Zacks, Alkermes reported break-even earnings for the second quarter of 2026, a significant change from the $0.52 per share earned in the same period last year. Despite this, revenues beat expectations, growing nearly 27% to $496.00 million.

Looking ahead, Alkermes reaffirms its 2026 revenue guidance, projecting between $1.73 billion and $1.84 billion. The company is also advancing its drug candidate, alixorexton, into late-stage phase III studies for narcolepsy. This is a critical step in the long process of getting a new drug approved for sale, impacting future ALKS stock performance.